Innovating colorectal cancer screening, CRCbioscreen develops stool-based tests to detect high-risk precursor lesions. Their research, led by experts from the Netherlands Cancer Institute and based on Amsterdam UMC technology, aims to improve early cancer detection. CRCbioscreen’s tests could potentially replace current national screening programs. The company is committed to advancing oncology diagnostics through innovative biomarker research.